Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2006 Nov;51(11):1904-9.
doi: 10.1007/s10620-006-9284-0. Epub 2006 Sep 15.

A comparison between sodium alginate and magaldrate anhydrous in the treatment of patients with gastroesophageal reflux symptoms

Affiliations
Randomized Controlled Trial

A comparison between sodium alginate and magaldrate anhydrous in the treatment of patients with gastroesophageal reflux symptoms

Edoardo G Giannini et al. Dig Dis Sci. 2006 Nov.

Abstract

The aims of the present study were to compare effects of sodium alginate and the antacid magaldrate anhydrous in adults with gastroesophageal reflux (GOR) symptoms. Patients with heartburn and/or acid regurgitation for at least 3 days in the week before the study started (n=203) were randomized to receive a single dose of sodium alginate or magaldrate anhydrous at the onset of symptoms during a 3-day run-in period. Patients with symptoms during the run-in (n=191) were rerandomized to receive a 14-day treatment with either drug given as four daily doses. A speed of action < or =30 min was significantly more frequent among patients in the alginate group (49.4% vs. 40.4%; P=0.0074). A trend toward a more prolonged duration of action (median: 16.5 vs. 12.7 hr) and a greater sum of the symptom intensity difference (median: 40.0 vs. 31.0) was observed in the sodium alginate group. Total disappearance of symptoms was reported in 81.6% and 73.9% of patients in the sodium alginate group and magaldrate group, respectively. We conclude that sodium alginate was faster than magaldrate in relieving GRO symptoms and showed a tendency toward a more prolonged duration of action and a higher level of efficacy.

PubMed Disclaimer

References

    1. Dig Dis Sci. 2003 Dec;48(12):2237-41 - PubMed
    1. Aliment Pharmacol Ther. 2005 Jan 1;21(1):29-34 - PubMed
    1. Aliment Pharmacol Ther. 2003 May 15;17(10):1309-17 - PubMed
    1. Int J Pharm. 2005 Apr 27;294(1-2):137-47 - PubMed
    1. J Pharm Pharmacol. 2002 Oct;54(10 ):1351-6 - PubMed

Publication types

MeSH terms

LinkOut - more resources